Hannover Medical School

E. Madan led experiments, data analysis, and manuscript writing. A.M.P., V.V., A.K., and P.B. contributed to experiments, data analysis, and manuscript preparation. J.W. handled biostatistical analysis and data interpretation. T.B. and D.A. focused on microscopy, data interpretation, and figure preparation. P.C.M., G.B., M.D.B., I.D., H.K., and D.O. assisted with biostatistical analysis and data interpretation. A. Gogna and A.B. helped with figure preparation and live-cell videos. M.L.P., M.Y., D.Z., S.P., S.K., K.B., P.M., I.C., E.A.F., A.K.P., S.M., C.J.P., A.L., M.N., S.C., K.G., K.C.G., and K.S.S. contributed to pathology data collection and analysis. T.F.A., E.G., A. Gustafsson, G.L., L.N., E.Y., and R.S.-F. worked on 3D scaffold and organoid experiments. K.D.P.D. assisted with PDX experiments. N.M., M.J.P., K.J.-J., and S.H. focused on exosome biology experiments. Z.S. and W.L.R. worked on multiplexing experiments. M.B. and P.J. handled FISH experiments. H.O.R., F.A.T., and R.B. contributed to MR imaging data analysis. K.G.A., J.A., G.X., G.S., and S. Singh designed and produced mAbs. S.D., C.L.d.S., A.M.F., D.T., S.R.G., K.P., G.G., G.L.W.G.R., and H.W. edited the manuscript. A.M.H., A.R., and C.L. worked on mass spec analysis. A.S. and P.B.F. provided laboratory resources and collaboration. G.M.C., Y.L., A.L.O., L.L., and A.A.T. handled CRISPR-off experiments. A.S.P., U.M., R.D., A.K.G., K.S., and D. Chelmow contributed to ovarian cancer expertise. R.P., J.K., S.R., H.R., S. Sayeed, K.P.K., D. Connolly, K.P.N., M.O.I., M.P.K., C.M., M.A., A.L.-B., D.J., K.D.M., A. Tzankov, S.B., E.A.R., and R.C.M. assisted with pathology data collection. A. Tsung and D.S. fostered clinical collaborations. J.T. provided mouse tumor models and funding. A.P.S., R.W., K.J.W., and E. Moreno helped with manuscript writing and funding. R.G. designed the study, organized collaborations, and provided overall supervision and funding.

A study reveals MX2 protein assembles structures in cells to lure and trap HIV-1 and herpes simplex virus-1, mimicking nuclear pore complexes to prevent viral spread.

Researchers discovered MX protein assembles decoy structures mimicking nuclear pores, trapping or puncturing HIV-1 and herpes simplex virus-1, preventing viral spread.

Researchers at VIB-UGent Center for Medical Biotechnology discovered MX protein assembles virus decoy structures mimicking nuclear pore complexes, trapping or puncturing HIV-1 and herpes simplex virus-1, potentially leading to new antiviral therapies.

SciSparc received FDA approval for a Phase IIb trial of SCI-110 in adults with Tourette syndrome, to be conducted at Yale, Hannover, and Tel Aviv medical centers. The trial aims to assess SCI-110's efficacy, safety, and tolerability, with subjects randomized 1:1 to receive SCI-110 or a placebo. The primary efficacy measure is tic severity reduction, and the safety goal is to analyze adverse events.

SciSparc's Phase IIb clinical trials for SCI-110, a potential therapy for Tourette Syndrome, have been approved by the FDA. The trial will be conducted at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center, focusing on efficacy, safety, and tolerability of the drug in adult patients.

SciSparc's FDA-approved Phase IIb clinical trials for SCI-110, targeting Tourette Syndrome, will proceed at Yale, Hannover Medical School, and Tel Aviv Sourasky Medical Center. The trial aims to assess SCI-110's efficacy, safety, and tolerability in adult patients.

FDA approves SciSparc's SCI-110 for Phase IIb clinical trials in treating Tourette Syndrome, based on promising Phase IIa results showing significant tic reduction.